Skip to content

Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01802541
Enrollment
127
Registered
2013-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2013-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Insulin Sensitivity, Type 2 Diabetes

Keywords

diacylglycerol oil, insulin sensitivity, type 2 diabetes, cardiovascular disease, risk factors

Brief summary

Diacylglycerol oil has been shown to lower postprandial and fasting serum triacylglycerol levels and reduce body fat. The investigators hypothesize that replacing dietary fat with diacylglycerol oil reduces excess body fat in type 2 diabetic patients and that diacylglycerol oil has a beneficial effect on cardiovascular risk factors in Chinese type 2 diabetic patients.

Interventions

DIETARY_SUPPLEMENTdiacylglycerol oil
DIETARY_SUPPLEMENTtriacylglycerol oil

Sponsors

Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years

Inclusion criteria

1. Type 2 diabetic patients, blood sugar levels were stabilized between 7.0-10.0 mmol/L 2. Male, aged 40 - 70 years old, Female, aged post-menopausal - 70 years old. 3. Overweight/obese patients (BMI 25 - 40 kg/m2) 4. Currently under diet therapy for diabetes mellitus 5. Understands the procedures and willing to participate in the study

Exclusion criteria

1. Patients who unwilling to give informed consent 2. Type 1 diabetic patients 3. Familial hyperlipemia patients or blood triacylglycerol concentration \> 400 mg/dl 4. Patients with a history of cardiovascular disease and/or arteriosclerotic disease 5. Patients with a history of cerebrovascular disease 6. Patients with serious hepatic disease and/or renal disease 7. Patients with malignancy 8. Participation in another clinical study within 30 days prior to screening period. 9. Has a condition the doctor in charge believes would interfere with evaluation of the subject, or may put subject at undue risk

Design outcomes

Primary

MeasureTime frame
insulin resistance120 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026